Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX)

CAPS Rating: 2 out of 5

A biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases with operations in the United States and Europe.

Recs

0
Player Avatar sunnyspot (71.38) Submitted: 2/5/2012 12:46:17 PM : Underperform Start Price: $11.39 IDIX Score: +13.61

Despite strong growth in recent months, Gilead Sciences beat them to the punch on hepatitis C, upon which Idenix had hung its hopes. A rebound may take a while.

Featured Broker Partners


Advertisement